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Some previous studies suggest a long term association between clarithromycin use and cardiovascular events. This study
investigates this association for clarithromycin given as part of Helicobacter pylori treatment (HPT).
METHODS
Our source population was the Clinical Practice Research Datalink (CPRD), a UK primary care database. We conducted a
self-controlled case series (SCCS), a case–time–control study (CTC) and a propensity score adjusted cohort study com-
paring the rate of cardiovascular events in the 3 years after exposure to HPT containing clarithromycin with exposure to
clarithromycin free HPT.
Outcomes were ﬁrst incident diagnosis of myocardial infarction (MI), arrhythmia and stroke. For the cohort analysis we included
secondary outcomes all cause and cardiovascular mortality.
RESULTS
Twenty-eight thousand ﬁve hundred and ﬁfty-two patients were included in the cohort. The incidence rate ratio of ﬁrst
MI within 1 year of exposure to HPT containing clarithromycin was 1.07 (95% CI 0.85, 1.34, P = 0.58) and within
90 days was 1.43 (95% CI 0.99, 2.09 P = 0.057) in the SCCS analysis. CTC and cohort results were consistent with
these ﬁndings.
CONCLUSIONS
There was some evidence for a short term association for ﬁrst MI but none for a long term association for any outcome.© 2016 The Authors. British Journal of Clinical Pharmacology published by John Wiley &
Sons Ltd on behalf of The British Pharmacological Society.
DOI:10.1111/bcp.12983
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
Risk of cardiovascular events with clarithromycinWHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Previous epidemiological studies suggest that clarithromycin is associated with an increased risk of cardiovascular events at least
1 year after exposure.
• A recent study in a Hong Kong population suggests that there is no long term risk, only a short term risk associated with
currently taking the drug.
WHAT THIS STUDY ADDS
• This study corroborates the ﬁndings of the Hong Kong study in a larger UK population that has been well validated for
cardiovascular outcomes.
• Clarithromycin is not associated with a long term increased risk of cardiovascular events.
• There is some evidence for an increased short term risk.Introduction
Clarithromycin is a very commonly prescribed antibiotic in
both primary and secondary care settings. As well as having
speciﬁc indications, it is one of the most commonly
prescribed alternatives for patients allergic to penicillin. The
summary of product characteristics states that clarithromycin,
along with other macrolides, can cause QT prolongation and
thereby increase the short term risk of cardiac arrhythmias.
However two recent papers have suggested an association
between clarithromycin exposure and a broad range of subse-
quent cardiovascular events that extends for at least 1 year
after taking the course of medication [1, 2]. This is incompati-
ble with temporary QT prolongation being the underlying
mechanism and if this association were causal, it could have
profound implications for clarithromycin prescribing.
It is possible that in previous studies people given
clarithromycin were generally frailer than people given other
antibiotics despite correction for measured confounders. This
type of indication bias is common in observational studies of
drug effects and can lead to ﬁndings of non-causal associa-
tions. To avoid this, we have chosen to restrict our investiga-
tion to the association between clarithromycin given as part
of Helicobacter pylori treatment (HPT) and subsequent cardio-
vascular events. The restriction to HPT regimes should reduce
confounding by indication, as the choice of HPT regime is
unlikely to be closely linked with a patient’s underlying risk
of cardiovascular outcomes. Furthermore, we employed three
study designs with complementary strengths and weaknesses
to guard further against conclusions based on potentially
biased results. A causal association should show a consistent
pattern across study designs whereas discordant ﬁndings
may suggest important bias. Finally, we have completed this
study protocol in a Hong Kong population cohort to ensure
generalizability to different ethnicities and to guard against
biases derived from a single health care database. [3].Methods
Clinical Practice Research Datalink (CPRD)
The CPRD is a large UK primary care electronic healthcare
records database widely validated for epidemiological
research [4]. A subset of the CPRD database has been linked
to the Ofﬁce of National Statistics (ONS) and Hospital
Episodes Statistics (HES) databases which provide cause ofdeath data and hospital discharge information, respectively.
We used the full CPRD database for all outcomes except for
mortality outcomes where we used this linked subset.
Selection of participants
Patients were selected from the population registered at partic-
ipating general practices that were up to research standard be-
fore January 2014. All patients exposed to HPT during the
registration period were included. Patients who had either ex-
posure or outcome recorded during their ﬁrst year of registra-
tion in the database were excluded from the cohort since
records entered close to registration could reﬂect historic data.
Exposure
Exposure to HPT was determined by prescription for all three
components of a triple therapy regime listed in the British
National Formulary (BNF) on the same day. It was considered
very unlikely to receive this particular combination of drugs
for any other indication. We included patients who received
courses of treatment lasting between 1 and 2 weeks duration.
Patients who received a prescription for a HPT regime
containing clarithromycin (CHPT) were the exposed group
and for the cohort design, patients who received a prescrip-
tion for a clarithromycin free HPT regime (NHPT) were the
unexposed comparator group. The comparator group was
chosen tominimize the risk of indication bias as both regimes
have the same indication. All regimes were taken from the
BNF and are listed in Appendix S1. There were insufﬁcient
patients with a speciﬁc Read code for H. pylori infection to
use these in our exposure deﬁnition. However, we conducted
a sensitivity analysis using the subset of patients who also
had a Read code for H. pylori to validate our approach.
Outcomes
First recorded incident diagnosis of myocardial infarction
(MI), arrhythmia and stroke were analyzed as separate out-
come measures for all three study designs. These outcomes
were selected as they were components of the composite out-
comes reported by Schembri et al. [2]. All subsequent diagno-
ses of the same event type were excluded to reduce the
possibility of a repeated entry of the same event. The validity
of recording MI in the CPRD has previously been conﬁrmed
by Herrett et al. [5]. However, they described a small delay be-
tween MI events coded in CPRD compared with the same
events coded in HES. It is possible that this delay might either
reduce the power of our analysis or result in a delayedBr J Clin Pharmacol (2016) 82 512–521 513
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self-controlled case series method and we conducted a sensi-
tivity analysis using this method in a subset of CPRD patients
who have linked HES records using HES MI dates.
All cause mortality and cardiovascular mortality were in-
cluded for the cohort design only since the self-controlled
methods would be biased for this outcome. Cardiovascular
mortality was obtained from linked ONS data, which was
available from 1 January 1998 to 10 January 2012 for a subset
of CPRD.Propensity adjusted cohort study
Patients entered this study from the day they ﬁrst received a
prescription for any form of HPT. They were followed up for
3 years. For all patients in the cohort follow-up was censored
at the ﬁrst date of any of the following: leaving the CPRD,
death, last data collection from the general practitioner (GP)
or at the next prescription for clarithromycin either alone or
as part of HPT.
A Poisson regression model was used to measure the rate
ratio of outcome occurrence for those exposed to CHPT com-
pared with NHPT. To control for confounding, a propensity
score was developed as detailed in Appendix S2. This was in-
cluded as a covariate in the ﬁnal outcome model. For the var-
iables smoking status, alcohol status and Body Mass Index
(BMI), there were some missing data and this was analyzed
by creating an unknown category. A sensitivity analysis using
just complete records was carried out. The distribution of pro-
pensity scores for both groups was examined (Appendix S3).
All patients whose scores fell outside of the overlapping re-
gion of both distributions were removed from the outcome
model. In addition the top and bottom 5% of each distribu-
tion was removed from the outcome model. These adjust-
ments were made because people treated contrary to
extreme scores may have important unmeasured characteris-
tics that could bias effect estimates [6]. We conducted a sensi-
tivity analysis without trimming the 5% tails of each
distribution to investigate the effect of this analysis decision.
A secondary analysis was performed where the study period
was stratiﬁed by time since exposure into time windows. These
strata were days 1–90, days 91–365, days 366–730 (years 1–2)
and days 731–1095 (years 2–3) post-exposure. This analysis
was designed to model any change in risk over time. There
was insufﬁcient power to look at shorter initial risk periods.Self-controlled case series study (SCCS)
This study design is derived from rate modelling using a
Poisson distribution and is analogous to cohortmethodology.
It relies on within person comparisons in a population with
both the cardiovascular event outcome and exposure to
CHPT [7, 8] Incidence rate ratios are derived, comparing the
rate of cardiovascular events during predeﬁned risk periods
following exposure to CHPT with that during all other ob-
served periods. In this case the risk period was deﬁned as the
ﬁrst year following exposure in this analysis. A major advan-
tage of this design is that it removes the potential confound-
ing effect of both recorded and unrecorded time invariant
characteristics between people. Age, which varies over time,
was adjusted for in the analysis (age bands are detailed in514 Br J Clin Pharmacol (2016) 82 512–521Appendix S4). The method relies on several assumptions.
These assumptions and our approach to handling them are
detailed in Appendix S5.
For this analysis, follow-up was from 1 year following
registration with the database until the patient died,
moved to a different general practice or the last data collec-
tion by the practice before January 2014. As with the
cohort design, a secondary analysis was undertaken where
several risk windows post-exposure were compared with
the baseline rate: days 1–30, days 31–90, days 91–365, days
366–730 (years 1–2) and days 731–1095 (years 2–3) post-
exposure.
Finally we employed a non-parametric SCCS design using
cubic splines that does not require a pre-speciﬁed risk period
to model the association between CHPT and ﬁrst MI. This
method allows better visualization of the proﬁle of relative
risk over time [9].
Case–time–control study (CTC)
This design, described by Suissa [10], is a variation of the case–
crossover study that controls for possible changes in exposure
trends over time. The comparison is between a case period
and a reference period within the same patient and the
control patients are used to remove any bias from underlying
prescription trends. Controls were matched on gender, age to
the nearest year, general practice and registration period.
A conditional logistic regression model including the
interaction between the case/control indicator and the time
period indicator variables was performed. In this model, the
effect of the exposure is given by the interaction term
whereas the effect of the time period in the absence of expo-
sure is given by the time period term.
Data analysis and power considerations
All analyses were conducted using Stata software, version 13
(StataCorp, College Station, TX, USA). Prior to undertaking
the analyses we estimated that we would have over 99%
power to detect a relative risk of 1.5 and 80% power to detect
a relative risk of 1.3 for the cohort analysis assuming the 1
year risk of MI is 4/1000 in adults (Coronary Heart Disease
Statistics 2010, BHF).
Ethics
Ethical approval was granted by the London School of Hy-
giene and Tropical Medicine Ethics Committee (PR/203/
203) and scientiﬁc approval was granted by the Independent
Scientiﬁc Advisory Committee of the Medicines and
Healthcare Products Regulatory Agency (ISAC Reference
14_066R).Results
Cohort study
We identiﬁed 37 530 patients in the database with at least one
prescription of HPT. Figure 1 is a ﬂow diagram of patients ex-
cluded from the cohort. Twenty-eight thousand ﬁve hundred
and ﬁfty-two patients were included in the analysis. Of these
26 029 (91%) received CHPT and 2523 (9%) received NHPT.
Figure 1
Flow chart for the propensity score adjusted cohort analysis of ﬁrst MI
Risk of cardiovascular events with clarithromycinFor both groups the mean age at exposure was 53 years and
the median follow-up was 3 years. For the CHPT group the
mean age at ﬁrst MI was 67 years compared with 69 years
for the NHPT group. Table 1 shows the baseline characteris-
tics for these groups (Appendix S6 shows the baseline charac-
teristics for the cohort before the exclusions listed above).
There were no large differences between the two groups on
any characteristic.
Table 2 shows the results of Poisson regression analysis.
For ﬁrst MI, the rate ratio for CHPT compared with NHPT ex-
posure was 0.75 (95% CI 0.45, 1.24, P = 0.26) after propensity
score adjustment. There was no association.
For ﬁrst arrhythmia the adjusted rate ratio was 0.37 (95%
CI 0.22, 0.63, P = 0.001).
For ﬁrst stroke the adjusted rate ratio was 0.47 (95% CI
0.26, 0.84, P = 0.01). There was good evidence that CHPT
was associated with a reduced incidence of both ﬁrst arrhyth-
mia and ﬁrst stroke. For all causemortality and cardiovascular
mortality there was no evidence of an association in any of
the analyses (see Table 2).
Appendix S7 shows the results for all outcomes stratiﬁed
by time. There was some evidence for a protective association
for ﬁrst arrhythmia between years 1 and 2 post-exposure.Self-controlled case series study (SCCS)
Nine hundred and sixty-two patients were both exposed to
CHPT and had a ﬁrst MI within the registration period in
CPRD. They had a mean follow-up time of 14 years. The age
adjusted rate ratio for incident ﬁrst MI in the year after expo-
sure to CHPT compared with the rest of follow-up was 1.07
(95% CI 0.85, 1.34, P = 0.58). There was no association be-
tween CHPT and ﬁrst MI in the ﬁrst year after taking it. In
the secondary analysis comparingmultiple risk windows over
the 3 years following exposure to baseline there was some ev-
idence of an increased risk at year 1 to 2 post-exposure with a
rate ratio of 1.27 (95% CI 1.01, 1.61, P = 0.04). These results
are shown in Table 3. A non-parametric SCCS analysis
showed no association between exposure to CHPT and ﬁrst
MI and this is shown in Figure 2. As the risk windows
1–30 days post-exposure and 31–90 days post-exposure
contained very few events these were combined post hoc to
improve power. The incidence rate ratio for days 1–90 post-
exposure was 1.43 (95% CI 0.99, 2.09, P = 0.057), suggesting
a possible association between exposure to CHPT and subse-
quent MI within 90 days.
Five hundred and ﬁfty-two patients were both exposed to
CHPT and had a ﬁrst arrhythmia within the registrationBr J Clin Pharmacol (2016) 82 512–521 515
Table 1
Baseline characteristics for patients included in the cohort study be-
tween 1991 and 2013 with a median follow-up of 3 years
Characteristic
Clarithromycin
containing HPT
regime
Clarithromycin-
free HPT regime
n (%) n (%)
Gender
Male 12386 (47.6%) 1196 (47.4%)
Female 13643 (52.4%) 1327 (52.6%)
Age
0–40 years 6114 (23.5%) 592 (23.5%)
40–50 years 5365 (20.6%) 518 (20.5%)
50–60 years 5343 (20.5%) 529 (21.0%)
60–70 years 4976 (19.1%) 478 (19.0%)
70–80 years 3135 (12.0%) 301 (11.9%)
>80 years 1096 (4.2%) 105 (4.2%)
Smoking status
non-smoker 10392 (39.9%) 1052 (41.7%)
current smoker 7409 (28.5%) 632 (25.1%)
ex-smoker 7884 (30.3%) 812 (32.2%)
unknown 344 (1.3%) 27 (1.1%)
Alcohol status
non-drinker 4330 (16.6%) 442 (17.5%)
ex-drinker 1133 (4.4%) 120 (4.8%)
current drinker
(unknown quantity) 102 (0.4%) 11 (0.4%)
<2 u day–1 4387 (16.9%) 447 (17.7%)
3-6 u day–1 10900 (41.9%) 1016 (40.3%)
>6 u day–1 2588 (9.9%) 234 (9.3%)
unknown 2589 (10.0%) 253 (10.0%)
Body mass index (kg m2)
normal (18.5–25) 9642 (37.0%) 941 (37.3%)
overweight (25–30) 8884 (34.1%) 856 (33.9%)
obese I (30–35) 3585 (13.8%) 367 (14.6%)
obese II (35–40) 1109 (4.3%) 115 (4.6%)
obese III (>40) 472 (1.8%) 44 (1.7%)
unknown 2337 (9.0%) 1200 (7.9%)
Consulted GP in year
before exposure 25948 (99.7%) 2514 (99.6%)
History of
cardiovascular
disease 4226 (16.2%) 366 (14.5%)
History of heart
failure 755 (2.9%) 59 (2.3%)
History of arrhythmia 1434 (5.5%) 127 (5.0%)
History of
hypertension 8240 (31.7%) 783 (31.0%)
History of COPD 1682 (6.5%) 167 (6.6%)
History of asthma 3615 (13.9%) 350 (13.9%)
History of
hyperlipidaemia 4605 (17.7%) 416 (16.5%)
History of diabetes
mellitus 3734 (14.4%) 342 (13.6%)
History of cancer 4884 (18.8%) 461 (18.3%)
History of NSAID use 1942 (7.5%) 167 (6.6%)
(continues)
Table 1
(Continued)
Characteristic
Clarithromycin
containing HPT
regime
Clarithromycin-
free HPT regime
n (%) n (%)
History of oral
corticosteroid use 383 (1.5%) 36 (1.4%)
History of
antipsychotic use 854 (3.3%) 81 (3.2%)
History of
antidepressant use 3101 (11.9%) 294 (11.7%)
History of lipid
lowering drug use 2948 (11.3%) 336 (13.3%)
History of
anticoagulant use 226 (0.9%) 32 (1.3%)
History of
antiplatelet use 2156 (8.3%) 242 (9.6%)
History of nitrate use 649 (2.5%) 56 (2.2%)
History of digoxin use 146 (0.6%) 15 (0.6%)
History of
antiarrhythmic
drug use 59 (0.2%) 6 (0.2%)
History of
β-adrenoceptor
blocker use 2192 (8.4%) 230 (9.1%)
History of thiazide
diuretic use 1892 (7.3%) 181 (7.2%)
History of calcium
channel blocker use 2072 (8.0%) 216 (8.6%)
History of ACEI/
ARB use 2843 (10.9%) 316 (12.5%)
History of loop
diuretic use 718 (2.8%) 62 (2.5%)
Total 26029 2523
ACEI angiotensinc enzyme inhibitor, ARB angiotensin receptor blocker,
COPD chronic obstructive pulmonary disease, HPT Helicobacter
pylori treatment, NSAID non-steroidal anti-inﬂammatory drug
A. A. Root et al.
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The age adjusted rate ratio for incident ﬁrst arrhythmia in the
year after exposure to CHPT compared with the rest of follow-
up was 1.24 (95% CI 0.92, 1.68, P = 0.16). There was no
association between CHPT and ﬁrst arrhythmia in the ﬁrst
year after taking it. In the secondary analysis comparing mul-
tiple risk windows over the 3 years following exposure to
baseline there was evidence of an increased risk from days
30–90 post-exposure with a rate ratio of 2.04 (95% CI 1.19,
3.51, P = 0.01). There was no evidence of an increased risk
during other time windows examined.
Appendix S8 shows the SCCS analysis for ﬁrst stroke.
There was no evidence of an association between CHPT and
increased risk of stroke.Case–time–control study (CTC)
Eighty-two thousand seven hundred and eight patients had a
ﬁrst MI during the registration period. These were matched to
Table 2
Results of the propensity score adjusted cohort analysis using Poisson regression
Patients (n) Patient-years Events (n) Crude IRR (95% CI) PS Adjusted IRR (95% CI)
First MI
CHPT 26 029 62118.98 174 0.89 (0.54, 1.44) P = 0.62 0.75 (0.45, 1.24) P = 0.26
NHPT 2523 5688.98 18 1.00
First stroke
CHPT 26 686 63847.36 68 0.38 (0.22, 0.66) P = 0.001 0.47 (0.26, 0.84) P = 0.01
NHPT 2540 5746.98 16 1.00
First arrhythmia
CHPT 26 586 63581.67 95 0.43 (0.26, 0.69) P = 0.001 0.37 (0.22, 0.63) P = 0.001
NHPT 2527 5702.77 20 1.00
All cause mortality
CHPT 26 827 64235.69 2621 1.09 (0.95, 1.25) P = 0.22 0.97 (0.84, 1.12) P = 0.66
NHPT 2582 5851.81 219 1.00
Cardiovascular mortality
CHPT 11 616 27729.71 416 1.05 (0.73, 1.50) P = 0.80 0.93 (0.64, 1.34) P = 0.69
NHPT 1058 2234.28 32 1.00 1.00
CHPT Helicobacter pylori treatments containing clarithromycin, CI conﬁdence interval, HPT Helicobacter pylori treatment, IRR incidence rate ratio, MI
myocardial infarction, NHPT clarithromycin free Helicobacter pylori treatment
Table 3
Results of the self-controlled case series analysis for the outcomes of ﬁrst MI and ﬁrst arrhythmia
Patients (n) Patient-years Events (n) Age adjusted IRR (95% CI)
Primary outcome: First MI
(median follow-up 14.0 years)
Single risk window
Baseline 962 12 718 876 1
1 year post-exposure 961 932.5 84 1.07 (0.85, 1.34) P = 0.58
Multiple risk window
Baseline 962 11 104 731 1
days 1–30 post-exposure 961 81.08 9 1.32 (0.6, 2.55) P = 0.41
days 31–90 post-exposure 954 159.42 20 1.50 (0.96, 2.35) P = 0.08
days 91–365 post-exposure 941 694.45 55 0.97 (0.74, 1.29) P = 0.84
years 1–2 post-exposure 886 843.08 85 1.27 (1.01, 1.61) P = 0.04
years 2–3 post-exposure 800 768.74 60 1.01 (0.77, 1.33) P = 0.92
Secondary outcome: ﬁrst arrhythmia
(median follow-up 15.0 years)
Single risk window
Baseline 552 7727.83 498 1
1 year post-exposure 552 542.11 50 1.24 (0.92, 1.68) P = 0.16
Multiple risk window
Baseline 552 6761.63 432 1
days 1–30 post-exposure 552 46.57 5 1.42 (0.58, 3.44) P = 0.44
days 31–90 post-exposure 548 91.83 14 2.04 (1.19, 3.51) P = 0.01
days 91–365 post-exposure 543 405.14 31 0.99 (0.68, 1.45) P = 0.97
years 1–2 post-exposure 514 500.77 35 0.89 (0.63, 1.27) P = 0.53
years 2–3 post-exposure 473 464 31 0.83 (0.57, 1.2) P = 0.33
All IRRs are age adjusted and derived from conditional Poisson regression. MI myocardial infarction, CI conﬁdence interval, IRR incidence rate ratio
Risk of cardiovascular events with clarithromycincontrols aiming for 4 : 1 matching. Seven thousand seven
hundred and ninety-seven patients did not have a suitable
match and were excluded from the analysis. One hundredand forty-two patients were excluded because they did not
have 3 years of follow-up before the ﬁrst MI. The remaining
74 769 cases were matched to 258 696 controls.Br J Clin Pharmacol (2016) 82 512–521 517
Figure 2
Non-parametric self-controlled case series analysis of the relative
incidence of ﬁrst myocardial infarction after exposure to
clarithromycin containing Helicobacter pylori therapy. The black
dashed lines represent upper and lower 95% conﬁdence intervals
surrounding the relative incidence estimate. The red dashed line
represents the null value
A. A. Root et al.The odds ratio for exposure to CHPT in the year before
ﬁrst MI compared with the reference period between 1 and
2 years before MI was 0.86 (95% CI 0.59, 1.26, P = 0.44).
There was no association between exposure to CHPT and
ﬁrst MI within a year. We carried out a post hoc analysis
comparing the current period 0–90 days before ﬁrst MI
with a reference period 91–180 days before ﬁrst MI toTable 4
Results of case-time-control analysis for all outcomes
Patients (n) Patient-years
First MI
Exposure effect 33 465 737 176
Period effect
Case-crossover equivalent
First stroke
Exposure effect 53 430 108 812
Period effect
Case-crossover equivalent
First arrhythmia
Exposure effect 87 256 179 566
Period effect
Case-crossover equivalent
Conditional logistic regression analysis. Exposure effect OR for the effect of ex
the two periods. Period effect OR for period indicator variable: this represent
riods that is not due to exposure effects. Case-crossover equivalent crude OR fo
total effect comparing periods before adjusting for differences between perio
analysis. OR odds ratio, MI myocardial infarction, CI conﬁdence interval.
518 Br J Clin Pharmacol (2016) 82 512–521mirror the post hoc SCCS analysis described above. The
odds ratio comparing these periods was 1.32 (95% CI
0.62, 2.80, P = 0.74).
There was no association between exposure to CHPT and
either ﬁrst arrhythmia or ﬁrst stroke. Table 4 shows the results
of the CTC analysis for all outcomes.
Sensitivity analyses
Three hundred and ﬁfty-nine CPRD patients with linked HES
records were exposed to clarithromycin containing HPT and
had a ﬁrst MI event within follow-up. An SCCS analysis on this
cohort using event dates recorded in HES showed an age
adjusted rate ratio for incident ﬁrst MI in the 30 days after
exposure to CHPT compared with the rest of follow-up of 3.77
(95% CI 1.85, 7.68, P < 0.001). There was no association with
any other time periods. The results are shown in Appendix S9.
This sensitivity analysis was not conducted for the ﬁrst
arrhythmia outcome because the databases were often
discordant with respect to the ﬁrst arrhythmia event. In
particular, many ﬁrst arrhythmias were coded in CPRD but not
in HES which probably reﬂects the fact that many of these cases
did not require inpatient admission. These discordant events
might possibly reﬂect historical events coded more recently.
None of the other sensitivity analyses conducted con-
ﬂicted with our main analyses. The results are not shown.Discussion
This study found no evidence that clarithromycin in the con-
text of HPT was associated with the ﬁrst MI within 1 year of
exposure. There was, however, some evidence of a short lived
increased risk of ﬁrst MI and ﬁrst arrhythmia within 90 days
of exposure in the SCCS. The statistical evidence for this
result was weak and it should be treated with caution. In par-
ticular, arrhythmia events were discordant when comparedEvents (n) OR (95% CI)
74 769 0.86 (0.59, 1.26) P = 0.44
1.08 (0.90, 1.31) P = 0.41
0.93 (0.67, 1.29) P = 0.68
11 025 1.17 (0.58, 2.36) P = 0.67
1.10 (0.67, 1.82) P = 0.70
1.29 (0.78, 2.11) P = 0.32
18 137 1.46 (0.79, 2.70) P = 0.23
0.96 (0.64, 1.43) P = 0.84
1.40 (0.88, 2.24) P = 0.16
posure after adjusting for differences in prescription patterns between
s the effect of the difference in prescription rates between the two pe-
r exposure period compared with reference period: this represents the
ds due to underlying prescription patterns i.e. a simple case-crossover
Risk of cardiovascular events with clarithromycinwith hospital data and although this is likely to represent
milder arrhythmias that did not require hospital admission
the possibility remains that there was increased case ﬁnding
by clinicians aware of recent clarithromycin use and the
potential association with arrhythmia.
Despite these caveats, it is consistent with the summary of
product characteristics document for clarithromycin, which
lists prolonged QT interval as a recognized side effect.
Prolonged QT interval is a cause of arrhythmia and arrhyth-
mia in turn can precipitate MI.
The sensitivity analysis of patients with linked HES
records with more accurate HES outcome dates revealed a
strong short term effect within 30 days of exposure. This sug-
gests that there is some temporal lag in CPRD event recording
and the true risk period might be much shorter.
The cohort analysis suggested a protective effect of CHPT on
the incidence of ﬁrst stroke and ﬁrst arrhythmia. However this
ﬁnding would not be predicted by the known pharmacology
of clarithromycin. Moreover it was not conﬁrmed by the SCCS
or CTC analyses and should be viewed with caution. Clinicians
will be aware of the association between clarithromycin and
prolonged QT interval. It is possible that patients at high risk
of ventricular arrhythmia, for example with a relevant family
history, would be prescribedNHPTpreferentially and this would
manifest as a protective effect in a cohort analysis comparing pa-
tients prescribed CHPT with patients prescribed clarithromycin
free HPT. This may not be captured by the propensity score for
two reasons. Firstly, there is likely to be signiﬁcant under-
reporting of risk factors for arrhythmia such as family history
of ventricular arrhythmia in the CPRD. There were less than ﬁve
patients in the cohort with a code for this. Secondly, the propen-
sity score adjusted for history of any arrhythmia. This includes
all subtypes and is dominated by atrial ﬁbrillation. This is an
imperfect covariate. However, as there were only 10 patients in
the cohort with codes for ventricular arrhythmia or long QT
syndrome, including a more speciﬁc covariate was not feasible
in this study. Since arrhythmia is a cause of stroke this could also
be a cause of the protective effect seen for stroke also. Compar-
ing the discordant results of the cohort and the self-controlled
methods we feel that it is more plausible that the cohort suffers
from residual uncontrolled confounding than the alternative
explanation that clarithromycin is protective for arrhythmia
and stroke and that the self-controlled designs were biased
towards the null.
Comparison between study designs
All three methods were consistent in not ﬁnding any long
term harmful association between CHPT and any of the study
outcomes.
The SCCS analysis showed some evidence of short term risk
of MI and arrhythmia that was not demonstrated in the cohort
analysis.However, the cohort analysis lacked power as evidenced
by very wide conﬁdence intervals which were unable to rule out
potentially large effects. A post hoc CTC analysis of the short
term risk period for MI suggested an effect estimate consistent
with the SCCS but with conﬁdence intervals crossing unity.
Strengths and weaknesses
The strengths of this study are that it draws from a large
representative primary care population and therefore isgeneralizable to the UK population. The exposure is restricted
to an indication which is unlikely to be biased by acute infec-
tion and it employs several analytic methods with different
susceptibilities to bias to answer the same question which
reduces the risk that congruent ﬁndings across methods are
due to bias.
A weakness of the cohort analysis was that the NHPT
group was much smaller than the CHPT group. This compro-
mised the power of this analysis. NHPT regimes all contain
metronidazole. It is likely that these are less often prescribed
because metronidazole is more likely to cause gastrointestinal
side effects such as nausea and vomiting. Additionally, the
BNF recommends these regimes as second line and so they
are likely to be prescribed only for patients with allergy to
HPT regimes containing clarithromycin. We do not know of
any reason why this prescribing behaviour would result in
differences in baseline cardiovascular risk between groups
and the baseline characteristics measures were similar
(Table 1). The consistency with the two self-controlled analy-
ses suggests that any bias from this is unlikely to have signif-
icantly affected the analysis.
The CTC analysis compared the ﬁrst MI in the year follow-
ing exposure to a baseline period between 1 and 2 years
following exposure. This would be sensitive to a risk within
the year following exposure but would underestimate a lon-
ger term risk as this would make the exposure period more
similar to the baseline period.
The SCCS analysis can be biased if the outcome event
causes signiﬁcant censoring of subsequent exposures. This
can occur with events that are associated with subsequent
death. Although there is an increased mortality following
ﬁrst MI this represented a small proportion of the cohort (less
than 10% died in the year after ﬁrst MI). Previous studies have
shown that the increased mortality following ﬁrst MI is not
sufﬁcient to cause signiﬁcant bias [11, 12]. We performed a
sensitivity analysis excluding patients who died in the ﬁrst
30 days following ﬁrst MI and found no difference in the
study estimates.
This study was restricted to clarithromycin given as part
of HPT. While this restriction was employed to reduce
confounding by acute infection, the results are only strictly
applicable to this particular indication. However, there is no
good reason to suppose that adverse effects of taking
clarithromycin would differ by indication.
For the outcome of ﬁrst arrhythmia, there is already
evidence that clarithromycin prolongs the QT interval and
this would be expected to cause certain arrhythmia subtypes.
In this study we do not have sufﬁciently detailed data on
arrhythmia subtype to conﬁrm whether the short term asso-
ciation we reported was entirely due to this potentially causal
mechanism. If this were the only underlying causal mecha-
nism, our broad outcome deﬁnition of all ﬁrst arrhythmias
would be expected to underestimate the strength of this
causal association with speciﬁc arrhythmia subtypes such as
torsades de pointes.
The outcomes measured in this study were ﬁrst occur-
rence of the respective cardiovascular event. Therefore, the
ﬁndings of this study are only strictly applicable to patients
with no history of that particular cardiovascular event.
However, other well established cardiovascular risk factors,
such as hypertension and smoking, carry the same relativeBr J Clin Pharmacol (2016) 82 512–521 519
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there are no grounds to suspect a different effect from expo-
sure to clarithromycin for patients with a cardiovascular
event history compared with those who have no such history.Comparison with previous studies
Jespersen conducted an RCT investigating the possible bene-
ﬁt of clarithromycin in secondary prevention of MI [1]. None
of the primary or secondary outcomes of the study showed
any effect. However they reported an increased risk of both
cardiovascular mortality and a tertiary composite outcome
(including cardiovascular mortality, MI, stroke, unstable an-
gina and peripheral vascular disease). This association could
therefore be vulnerable to multiple testing.
Schembri et al. reported two cohorts comparing
clarithromycin with other antibiotics to treat pneumonia
and infective chronic obstructive pulmonary disease exacer-
bations, respectively [2]. It is possible that this study was sus-
ceptible to indication bias where frailer patients could have
been preferentially given clarithromycin over comparator an-
tibiotics such as amoxicillin and this frailty might not have
been adequately captured by the measured covariates.
Svanstrom et al. performed a propensity score adjusted
cohort analyses comparing the risk of cardiac death after
exposure to clarithromycin with exposure to penicillin V
[13]. They found an increased risk of cardiac death during
current use (adjusted rate ratio 1.76, 95% CI 1.08, 2.85) that
did not persist in the 30 days following the end of treatment.
They repeated the analysis substituting roxithromycin for
clarithromycin and did not ﬁnd any association (adjusted
rate ratio 1.04, 95% CI 0.72, 1.51). They concluded that
clarithromycin was associated with an acute cardiac risk that
did not persist after treatment was stopped. In this study
there were clear baseline differences between the clarith-
romycin group and the penicillin V control group, the latter
being younger, on less medication and having less respiratory
illness. Therefore, the acute risk could have been related to
these baseline differences.
Finally, we looked at this association in a Hong Kong
population employing a similar protocol [3]. Due to the
smaller size of the Hong Kong database the cohort method
could not be applied to H. pylori treatment only. Instead, the
self-controlled methods were applied to a H. pylori treatment
cohort and a propensity score controlled cohort method was
used to compare clarithromycin with amoxicillin for any
indication. This study showed increased risk of MI during
current use of clarithromycin in all study designs but no long
term risk after ﬁnishing the course. As with the study by
Schembri et al. [2] discussed above, the cohort method is
susceptible to indication bias. However, the congruence with
self-controlled methods makes this less likely here.
Our cohort was slightly younger than the ﬁrst two papers
(mean 53 years compared with 65 and 72 years, respectively)
and comparable with the latter two. The spread of ages in our
study was appreciably wider (SD 16 years compared with
10.3 years in Jespersen [1] and 9.6 years in Svanstrom et al.
[13]). This suggests that our study encompasses a broader
cross-section of the population than the previous studies.
The study we report does not conﬁrm the long term risk of
clarithromycin suggested by Jespersen [1] and Schembri et al. [2].520 Br J Clin Pharmacol (2016) 82 512–521However, we cannot rule out a short term increased risk of
MI and arrhythmia, which is consistent with Svanstrom
et al. [13] and Wong et al. [3].Clinical implications
Clarithromycin is widely used in UK primary care for a range of
indications. The suggestion of a raised long term cardiovascular
risk was therefore a major concern. This study does not support
this long term association. The SCCS analysis was compatible
with a short term risk of both MI and arrhythmia, as expected,
given the known pharmacology of clarithromycin. The SCCS
method cannot directly provide absolute estimates of risk. How-
ever, if the risk ofMI in the cohort group takingNHPT is used as a
baseline comparator, this analysis would be compatible with an
absolute rate increase forMI of three events per 10000 treatment
courses (assuming amaximum risk period of 90 days per course).
For ﬁrst arrhythmia the absolute rate increase would be eight
events per 10000 treatment courses. At present, the Summary
of Product Characteristics for clarithromycin advises caution
whenprescribing clarithromycin in patientswith coronary heart
disease and recommends not prescribing clarithromycin to
patients with a history of ventricular arrhythmia.
In conclusion this study found no long term association
between clarithromycin prescribed as part of HPT and cardio-
vascular events in a large UK primary care cohort. Our results
are consistent with a short term increased risk of MI and
arrhythmia within 90 days of exposure.Availability of data and materials
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